EcoDrugPlus

Tyrosine-Protein Kinase Jak2

Ensembl ID : ENSONIG00000016948
Gene Symbol: LOC100692564
4 Cross references
194 Possible Orthologues:

Tyrosine-Protein Kinase Jak2

Ensembl ID : ENSONIG00000003957
Gene Symbol: LOC100710044
4 Cross references
199 Possible Orthologues:

Tyrosine-Protein Kinase Fyna

Ensembl ID : ENSONIG00000001335
Gene Symbol: LOC100691175
3 Cross references
191 Possible Orthologues:

Uncharacterized Loc100712331

Ensembl ID : ENSONIG00000038264
Gene Symbol: LOC100712331
2 Cross references
190 Possible Orthologues:

Urotensin 2 Receptor

Ensembl ID : ENSONIG00000021202
Gene Symbol: UTS2R
4 Cross references
97 Possible Orthologues:

Utrophin

Ensembl ID : ENSONIG00000013377
Gene Symbol: UTRN
1 Cross references
270 Possible Orthologues:

V-Akt Murine Thymoma Viral Oncogene Homolog 2, Like

Ensembl ID : ENSONIG00000004786
Gene Symbol: AKT2L
1 Cross references
161 Possible Orthologues:

Vascular Endothelial Growth Factor Ab

Ensembl ID : ENSONIG00000037217
Gene Symbol: VEGFAB
1 Cross references
201 Possible Orthologues:

Vitamin D Receptor

Ensembl ID : ENSONIG00000009200
Gene Symbol: VDR
3 Cross references
388 Possible Orthologues:

Vitamin D3 Receptor B

Ensembl ID : ENSONIG00000019378
Gene Symbol: LOC100695813
4 Cross references
392 Possible Orthologues:

Vitamin K Epoxide Reductase Complex Subunit 1

Ensembl ID : ENSONIG00000020085
Gene Symbol: LOC100706346
4 Cross references
190 Possible Orthologues:

Voltage-Dependent Calcium Channel Gamma-3 Subunit

Ensembl ID : ENSONIG00000042235
Gene Symbol: LOC100703474
3 Cross references
190 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).